clinical trial · NCT07385703
Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.·phase3·not yet recruiting·n = 752
AdenocarcinomaLM-302 InjectionTislelizumabOxaliplatin InjectionCapecitabine Tablets
brief summary
This study primarily evaluates the efficacy and safety of the LM-302 plus tislelizumab regimen versus tislelizumab plus chemotherapy in the treatment of previously untreated locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma patients with CLDN18.2 positivity.
started
Mar 1, 2026
primary completion
Oct 1, 2028
completion
May 1, 2030
last updated
Feb 4, 2026
official title
A Randomized, Open-Label, Multicenter Phase III Study of Tecotabart Vedotin Plus Tislelizumab Versus Tislelizumab Plus Chemotherapy as First-Line Treatment in Patients With CLDN18.2-Positive, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol